OXIDATION OF ACETAMINOPHEN TO N-ACETYL-P-AMINOBENZOQUINONE IMINE BY HUMAN CYP3A4

被引:252
作者
THUMMEL, KE
LEE, CA
KUNZE, KL
NELSON, SD
SLATTERY, JT
机构
[1] UNIV WASHINGTON,DEPT PHARMACEUT,BG-20,SEATTLE,WA 98195
[2] UNIV WASHINGTON,DEPT MED CHEM,SEATTLE,WA 98195
关键词
D O I
10.1016/0006-2952(93)90295-8
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
We have investigated: (a) the formation of N-acetyl-p-aminobenzoquinone imine (NAPQI) from acetaminophen (APAP) by reconstituted human liver CYP3A4, (b) the kinetics of NAPQI formation in microsomes prepared from four human livers varying in CYP1A2, 2E1 and 3A4 content determined by Western blot analysis, (c) the contribution of CYP3A4 to the total formation of NAPQI from 0.1 mM APAP in human liver microsomes using troleandomycin as a specific inhibitor, and (d) the relationship between the contribution of CYP3A4 to NAPQI formation and relative CYP3A4 content. The K(m) of CYP3A4 for APAP was found to be approximately 0.15 mM, similar to concentrations observed in humans after therapeutic doses of the drug. The kinetics of formation of NAPQI in human liver microsomes were complex; the lower K(m) was similar to that found for reconstituted CYP3A4. The contribution of CYP3A4 to total NAPQI formation varied from 1 to 20% among livers, and correlated with the relative CYP3A4 content, r2 = 0.88, P < 0.05. Our findings indicate that CYP3A4, the major P450 isoform in human liver and enterocytes, contributes appreciably to the formation of the cytotoxic metabolite NAPQI at therapeutically relevant concentrations of APAP and suggest that APAP may be a previously unrecognized inhibitor of this enzyme.
引用
收藏
页码:1563 / 1569
页数:7
相关论文
共 28 条
[1]  
BLOT HM, 1975, EUR J CLIN PHARMACOL, V8, P301
[2]   LONG-TERM ANTICONVULSANT THERAPY WORSENS OUTCOME IN PARACETAMOL-INDUCED FULMINANT HEPATIC-FAILURE [J].
BRAY, GP ;
HARRISON, PM ;
OGRADY, JG ;
TREDGER, JM ;
WILLIAMS, R .
HUMAN & EXPERIMENTAL TOXICOLOGY, 1992, 11 (04) :265-270
[3]  
Estabrook RW., 1972, METHODS PHARM, Vvol 2, P303
[4]  
FLEMING CM, 1992, MOL PHARMACOL, V41, P975
[5]  
FOLCH J, 1957, J BIOL CHEM, V226, P497
[6]   CLINICAL PHARMACOKINETICS OF PARACETAMOL [J].
FORREST, JAH ;
CLEMENTS, JA ;
PRESCOTT, LF .
CLINICAL PHARMACOKINETICS, 1982, 7 (02) :93-107
[7]  
GIBSON GG, 1978, J BIOL CHEM, V253, P5957
[8]   ROLE OF HUMAN CYTOCHROME-P-450-IIE1 IN THE OXIDATION OF MANY LOW-MOLECULAR-WEIGHT CANCER SUSPECTS [J].
GUENGERICH, FP ;
KIM, DH ;
IWASAKI, M .
CHEMICAL RESEARCH IN TOXICOLOGY, 1991, 4 (02) :168-179
[9]   RECONSTITUTION OF TESTOSTERONE OXIDATION BY PURIFIED RAT CYTOCHROME-P450P (IIIA1) [J].
HALVORSON, M ;
GREENWAY, D ;
EBERHART, D ;
FITZGERALD, K ;
PARKINSON, A .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1990, 277 (01) :166-180
[10]   CYTOCHROME-P-450 ISOZYME SELECTIVITY IN THE OXIDATION OF ACETAMINOPHEN [J].
HARVISON, PJ ;
GUENGERICH, FP ;
RASHED, MS ;
NELSON, SD .
CHEMICAL RESEARCH IN TOXICOLOGY, 1988, 1 (01) :47-52